COVID-19: Insights into Potential Vaccines

Microorganisms

Kok-Gan Chan¹  Hooi-Leng Ser²  Ke-Yan Loo²  JodiWoan-Fei Law²  LohTeng-Hern Tan²  Nurul-Syakima Ab Mutalib²  Learn-Han Lee²  Vengadesh Letchumanan²  SiewLi Teoh³ 

[1] Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia;Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia;School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Malaysia;

关键词: COVID-19;    coronavirus (CoV);    vaccines;    clinical trials;    passive immunotherapies;   

DOI  :  10.3390/microorganisms9030605

来源: DOAJ

【 摘 要 】

People around the world ushered in the new year 2021 with a fear of COVID-19, as family members have lost their loved ones to the disease. Millions of people have been infected, and the livelihood of many has been jeopardized due to the pandemic. Pharmaceutical companies are racing against time to develop an effective vaccine to protect against COVID-19. Researchers have developed various types of candidate vaccines with the release of the genetic sequence of the SARS-CoV-2 virus in January. These include inactivated viral vaccines, protein subunit vaccines, mRNA vaccines, and recombinant viral vector vaccines. To date, several vaccines have been authorized for emergency use and they have been administered in countries across the globe. Meanwhile, there are also vaccine candidates in Phase III clinical trials awaiting results and approval from authorities. These candidates have shown positive results in the previous stages of the trials, whereby they could induce an immune response with minimal side effects in the participants. This review aims to discuss the different vaccine platforms and the clinical trials of the candidate vaccines.

【 授权许可】

Unknown